Impact of Vitamin D3 Versus Placebo on Cardiac Structure and Function: A Randomized Clinical Trial.

What Was Tested

The paper reports a study of Vitamin D, K2, Magnesium and Zinc, published as a randomized controlled trial.

However, limited data exist from prospective human studies.

The researchers conducted a substudy of VITAL in which participants underwent echocardiography at baseline and 2 years.

Who Took Part

The study group was 25,871 individuals.

The age groups tagged for this paper are adults and middle-aged adults, both men and women.

How the Study Was Run

In design terms this was a randomized, double-blind and placebo-controlled study.

The individuals were allocated by chance, so the Vitamin D, K2, Magnesium and Zinc group and the comparison group should start out alike.

Neither the individuals nor the staff measuring them knew who was on Vitamin D, K2, Magnesium and Zinc, so expectations could not easily colour the readings.

Some individuals received a placebo instead of Vitamin D, K2, Magnesium and Zinc, giving a reference point.

What Was Measured

The primary end point was change in LV mass.

The subject headings attached to it are Cholecalciferol, Dietary Supplements, Vitamins, Vitamin D and Fatty Acids, Omega-3.

Author keywords: cardiac structure and function, echocardiography, n−3 fatty acids and randomized controlled trial.

What This Means in Plain Language

The paper is a randomized, double-blind and placebo-controlled study of Vitamin D, K2, Magnesium and Zinc in 25,871 individuals.

With several hundred people or more, it is a fairly large study for this kind of research.

The publication is from 2022 (Journal of the American Heart Association), a journal based in England.

More context: the Vitamin D, K2, Magnesium and Zinc compound page, all human trials.